These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Novel strategies for challenging scenarios encountered in managing myelofibrosis. Bose P; Mesa RA Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887 [TBL] [Abstract][Full Text] [Related]
23. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. Treliński J; Robak T Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159 [TBL] [Abstract][Full Text] [Related]
24. Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors. Cattaneo D; Iurlo A Front Immunol; 2021; 12():750346. PubMed ID: 34867980 [No Abstract] [Full Text] [Related]
25. A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases. Duminuco A; Torre E; Palumbo GA; Harrison C Curr Hematol Malig Rep; 2023 Oct; 18(5):176-189. PubMed ID: 37395943 [TBL] [Abstract][Full Text] [Related]
26. Achievements and future outlook for JAK inhibitors in polycythaemia vera. Cakmak I; Harrison C Expert Opin Pharmacother; 2023; 24(13):1491-1496. PubMed ID: 37343285 [TBL] [Abstract][Full Text] [Related]
27. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Tefferi A Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355 [TBL] [Abstract][Full Text] [Related]
29. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016 [TBL] [Abstract][Full Text] [Related]
30. JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target? Kucine N; Levine RL Ther Adv Hematol; 2011 Aug; 2(4):203-11. PubMed ID: 23556090 [TBL] [Abstract][Full Text] [Related]
31. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
32. The future of JAK inhibition in myelofibrosis and beyond. Mascarenhas JO; Cross NC; Mesa RA Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171 [TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera. Alchalby H; Kröger N Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953 [TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life. Padrnos L; Mesa RA Oncology (Williston Park); 2017 Jul; 31(7):521-9. PubMed ID: 28712096 [TBL] [Abstract][Full Text] [Related]
36. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases. Shi Y; Xu C Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958 [TBL] [Abstract][Full Text] [Related]
37. Long-acting interferon for myeloproliferative neoplasms - an update. Pai SG; Kaplan JB; Giles FJ Expert Rev Hematol; 2016 Oct; 9(10):915-7. PubMed ID: 27584865 [No Abstract] [Full Text] [Related]
38. A phase 1 study of the Janus kinase 2 (JAK2) Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680 [TBL] [Abstract][Full Text] [Related]